Fennec Pharmaceuticals Inc
FENC7.690USD
+0.030+0.39%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
215.80MMarket Cap
LossP/E TTM
More Details of Fennec Pharmaceuticals Inc Company
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Fennec Pharmaceuticals Inc Info
Ticker SymbolFENC
Company nameFennec Pharmaceuticals Inc
IPO dateJun 05, 2001
CEOHackman (Jeffrey S)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJun 05
AddressPO Box 13628
CityRESEARCH TRIANGLE PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27709
Phone19196364530
Websitehttps://fennecpharma.com/
Ticker SymbolFENC
IPO dateJun 05, 2001
CEOHackman (Jeffrey S)
Company Executives of Fennec Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Khalid Islam, Ph.D.
Mr. Khalid Islam, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
213.82K
--
Mr. Jeffrey S. (Jeff) Hackman
Mr. Jeffrey S. (Jeff) Hackman
Chief Executive Officer, Director
Chief Executive Officer, Director
15.00K
--
Dr. Pierre Sargis Sayad, Ph.D.
Dr. Pierre Sargis Sayad, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Marco Maria Brughera
Dr. Marco Maria Brughera
Independent Director
Independent Director
--
--
Dr. Jodi A. Cook
Dr. Jodi A. Cook
Independent Director
Independent Director
--
--
Mr. Robert C. Andrade
Mr. Robert C. Andrade
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris A. Rallis
Mr. Chris A. Rallis
Independent Director
Independent Director
--
--
Mr. Rostislav C. (Rosty) Raykov
Mr. Rostislav C. (Rosty) Raykov
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Khalid Islam, Ph.D.
Mr. Khalid Islam, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
213.82K
--
Mr. Jeffrey S. (Jeff) Hackman
Mr. Jeffrey S. (Jeff) Hackman
Chief Executive Officer, Director
Chief Executive Officer, Director
15.00K
--
Dr. Pierre Sargis Sayad, Ph.D.
Dr. Pierre Sargis Sayad, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Marco Maria Brughera
Dr. Marco Maria Brughera
Independent Director
Independent Director
--
--
Dr. Jodi A. Cook
Dr. Jodi A. Cook
Independent Director
Independent Director
--
--
Mr. Robert C. Andrade
Mr. Robert C. Andrade
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
9.65M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
ESSETIFIN S.p.A.
11.69%
Southpoint Capital Advisors LP
10.96%
Sonic GP LLC
7.05%
Solas Capital Management, LLC
6.41%
Rosalind Advisors, Inc.
6.08%
Other
57.81%
Shareholders
Shareholders
Proportion
ESSETIFIN S.p.A.
11.69%
Southpoint Capital Advisors LP
10.96%
Sonic GP LLC
7.05%
Solas Capital Management, LLC
6.41%
Rosalind Advisors, Inc.
6.08%
Other
57.81%
Shareholder Types
Shareholders
Proportion
Hedge Fund
32.68%
Corporation
11.69%
Investment Advisor
7.67%
Investment Advisor/Hedge Fund
4.28%
Individual Investor
1.85%
Private Equity
1.48%
Research Firm
0.53%
Pension Fund
0.14%
Bank and Trust
0.09%
Other
39.59%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
151
16.06M
64.02%
-67.11K
2025Q3
155
16.13M
64.33%
+454.00
2025Q2
158
16.13M
64.91%
+221.22K
2025Q1
162
15.90M
67.94%
-2.84M
2024Q4
161
16.14M
67.31%
+1.13M
2024Q3
157
15.01M
65.31%
+573.67K
2024Q2
151
14.43M
61.28%
+2.27K
2024Q1
135
14.54M
58.90%
-1.43M
2023Q4
128
14.92M
58.25%
+654.33K
2023Q3
128
14.27M
58.54%
+215.74K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
ESSETIFIN S.p.A.
3.99M
14.35%
--
--
Apr 07, 2025
Southpoint Capital Advisors LP
4.08M
14.65%
--
--
Jun 30, 2025
Sonic GP LLC
2.41M
8.65%
--
--
Apr 07, 2025
Solas Capital Management, LLC
2.23M
8.02%
-18.02K
-0.80%
Jun 30, 2025
Rosalind Advisors, Inc.
2.05M
7.35%
+262.80K
+14.74%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.10M
3.95%
-41.19K
-3.61%
Jun 30, 2025
The Vanguard Group, Inc.
967.09K
3.47%
+2.47K
+0.26%
Jun 30, 2025
AIGH Capital Management, LLC.
336.40K
1.21%
+70.08K
+26.31%
Jun 30, 2025
State Street Investment Management (US)
336.49K
1.21%
-1.64K
-0.48%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.04%
Franklin US Small Cap Multifactor Index ETF
0.02%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 Covered Call ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.04%
Franklin US Small Cap Multifactor Index ETF
Proportion0.02%
Global X Russell 2000 ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
Global X Russell 2000 Covered Call ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Fennec Pharmaceuticals Inc?
The top five shareholders of Fennec Pharmaceuticals Inc are:
ESSETIFIN S.p.A. holds 3.99M shares, accounting for 14.35% of the total shares.
Southpoint Capital Advisors LP holds 4.08M shares, accounting for 14.65% of the total shares.
Sonic GP LLC holds 2.41M shares, accounting for 8.65% of the total shares.
Solas Capital Management, LLC holds 2.23M shares, accounting for 8.02% of the total shares.
Rosalind Advisors, Inc. holds 2.05M shares, accounting for 7.35% of the total shares.
ESSETIFIN S.p.A. holds 3.99M shares, accounting for 14.35% of the total shares.
Southpoint Capital Advisors LP holds 4.08M shares, accounting for 14.65% of the total shares.
Sonic GP LLC holds 2.41M shares, accounting for 8.65% of the total shares.
Solas Capital Management, LLC holds 2.23M shares, accounting for 8.02% of the total shares.
Rosalind Advisors, Inc. holds 2.05M shares, accounting for 7.35% of the total shares.
What are the top three shareholder types of Fennec Pharmaceuticals Inc?
The top three shareholder types of Fennec Pharmaceuticals Inc are:
ESSETIFIN S.p.A.
Southpoint Capital Advisors LP
Sonic GP LLC
ESSETIFIN S.p.A.
Southpoint Capital Advisors LP
Sonic GP LLC
How many institutions hold shares of Fennec Pharmaceuticals Inc (FENC)?
As of 2025Q4, 151 institutions hold shares of Fennec Pharmaceuticals Inc, with a combined market value of approximately 16.06M, accounting for 64.02% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.31%.
What is the biggest source of revenue for Fennec Pharmaceuticals Inc?
In FY2025Q2, the -- business generated the highest revenue for Fennec Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
